This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Kibun Foods Inc., Nihon University. Active years: 2008-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2008-2016
Title: Kohei Suruga: Innovator in Therapeutic Agents for Dementia
Introduction
Kohei Suruga is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of therapeutic agents, particularly in the treatment of dementia. With a focus on innovative solutions, Suruga has been awarded 2 patents for his groundbreaking work.
Latest Patents
One of Suruga's latest patents is a therapeutic agent for dementia. This invention comprises a pharmaceutically active substance derived from a novel heme peptide. The invention provides a peptide with a potent NO-scavenging ability, which can be utilized in capturing and quantifying nitric oxide (NO). This peptide can serve as a diagnostic agent, prophylactic agent, or therapeutic agent for diseases involving NO. Additionally, it can be used as a research reagent and for measuring NO concentrations in the environment, as well as for treating and removing NO from the environment.
Career Highlights
Throughout his career, Kohei Suruga has worked with various organizations, including Kibun Foods Inc. and Nihon University. His experience in these institutions has allowed him to develop and refine his innovative ideas, contributing to advancements in therapeutic applications.
Collaborations
Suruga has collaborated with notable colleagues such as Yasuhiro Komatsu and Kazunari Kadokura. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise.
Conclusion
Kohei Suruga's contributions to the field of therapeutic agents, particularly for dementia, highlight his innovative spirit and dedication to improving healthcare solutions. His work continues to inspire advancements in medical research and treatment methodologies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
